1. Pharmacological or genetic inhibition of iNOS prevents cachexia‐mediated muscle wasting and its associated metabolism defects. Issue 7 (7th June 2021) Authors: Sadek, Jason; Hall, Derek T; Colalillo, Bianca; Omer, Amr; Tremblay, Anne‐Marie K; Sanguin‐Gendreau, Virginie; Muller, William; Di Marco, Sergio; Bianchi, Marco Emilio; Gallouzi, Imed‐Eddine Journal: EMBO molecular medicine Issue: Volume 13:Issue 7(2021) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. STAT3 promotes IFNγ/TNFα‐induced muscle wasting in an NF‐κB‐dependent and IL‐6‐independent manner. Issue 5 (6th March 2017) Authors: Ma, Jennifer F; Sanchez, Brenda J; Hall, Derek T; Tremblay, Anne‐Marie K; Di Marco, Sergio; Gallouzi, Imed‐Eddine Journal: EMBO molecular medicine Issue: Volume 9:Issue 5(2017) Page Start: 622 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The AMPK agonist 5‐aminoimidazole‐4‐carboxamide ribonucleotide (AICAR), but not metformin, prevents inflammation‐associated cachectic muscle wasting. Issue 7 (29th May 2018) Authors: Hall, Derek T; Griss, Takla; Ma, Jennifer F; Sanchez, Brenda Janice; Sadek, Jason; Tremblay, Anne Marie K; Mubaid, Souad; Omer, Amr; Ford, Rebecca J; Bedard, Nathalie; Pause, Arnim; Wing, Simon S; Di Marco, Sergio; Steinberg, Gregory R; Jones, Russell G; Gallouzi, Imed‐Eddine Journal: EMBO molecular medicine Issue: Volume 10:Issue 7(2018) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗